RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis
TSX-V:ROMJ - TSX Venture Exchange - CA78112W1005 - Common Stock - Currency: CAD
ROMJ gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. ROMJ has an average financial health and profitability rating. While showing a medium growth rate, ROMJ is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ROMJ has reported negative net income.
In the past year ROMJ had a positive cash flow from operations.
ROMJ had negative earnings in each of the past 5 years.
In multiple years ROMJ reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.79%, ROMJ is in line with its industry, outperforming 55.88% of the companies in the same industry.
Looking at the Return On Equity, with a value of -2.64%, ROMJ is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
ROMJ's Return On Invested Capital of 21.77% is amongst the best of the industry. ROMJ outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ROMJ is significantly above the industry average of 7.89%.
The 3 year average ROIC (19.33%) for ROMJ is below the current ROIC(21.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.79% | ||
| ROE | -2.64% | ||
| ROIC | 21.77% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 26.59%, ROMJ belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Gross Margin, with a value of 58.85%, ROMJ belongs to the top of the industry, outperforming 88.24% of the companies in the same industry.
In the last couple of years the Gross Margin of ROMJ has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.59% | ||
| PM (TTM) | N/A | ||
| GM | 58.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ROMJ is creating value.
Compared to 1 year ago, ROMJ has more shares outstanding
The number of shares outstanding for ROMJ has been increased compared to 5 years ago.
The debt/assets ratio for ROMJ has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.51, we must say that ROMJ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.51, ROMJ belongs to the top of the industry, outperforming 85.29% of the companies in the same industry.
ROMJ has a debt to FCF ratio of 6.91. This is a slightly negative value and a sign of low solvency as ROMJ would need 6.91 years to pay back of all of its debts.
The Debt to FCF ratio of ROMJ (6.91) is better than 70.59% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that ROMJ is not too dependend on debt financing.
ROMJ has a Debt to Equity ratio of 0.22. This is comparable to the rest of the industry: ROMJ outperforms 55.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 6.91 | ||
| Altman-Z | 1.51 |
ROIC/WACC2.29
WACC9.52%
2.3 Liquidity
ROMJ has a Current Ratio of 3.16. This indicates that ROMJ is financially healthy and has no problem in meeting its short term obligations.
ROMJ has a Current ratio of 3.16. This is in the better half of the industry: ROMJ outperforms 79.41% of its industry peers.
ROMJ has a Quick Ratio of 1.69. This is a normal value and indicates that ROMJ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.69, ROMJ is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.01% over the past year.
Looking at the last year, ROMJ shows a very strong growth in Revenue. The Revenue has grown by 29.78%.
Measured over the past years, ROMJ shows a very strong growth in Revenue. The Revenue has been growing by 29.14% on average per year.
EPS 1Y (TTM)69.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.53%
Revenue 1Y (TTM)29.78%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%39.21%
3.2 Future
ROMJ is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
ROMJ is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.75% yearly.
EPS Next Y-75%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.09%
Revenue Next 2Y16.75%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ROMJ. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ROMJ is valued cheaper than 100.00% of the companies in the same industry.
70.59% of the companies in the same industry are more expensive than ROMJ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.91 | ||
| EV/EBITDA | 1.99 |
4.3 Compensation for Growth
The decent profitability rating of ROMJ may justify a higher PE ratio.
A more expensive valuation may be justified as ROMJ's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ROMJ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ROMJ (7/11/2025, 7:00:00 PM)
0.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.9%
Inst Owner ChangeN/A
Ins Owners41.69%
Ins Owner ChangeN/A
Market Cap32.15M
Analysts80
Price Target1.12 (133.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-600%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.62 | ||
| P/FCF | 22.91 | ||
| P/OCF | 9.75 | ||
| P/B | 0.86 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | 1.99 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.02
FCFY4.37%
OCF(TTM)0.05
OCFY10.25%
SpS0.78
BVpS0.56
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.79% | ||
| ROE | -2.64% | ||
| ROCE | 30.24% | ||
| ROIC | 21.77% | ||
| ROICexc | 26.22% | ||
| ROICexgc | 27.97% | ||
| OM | 26.59% | ||
| PM (TTM) | N/A | ||
| GM | 58.85% | ||
| FCFM | 2.69% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
ROICexc(3y)24.75%
ROICexc(5y)N/A
ROICexgc(3y)26.66%
ROICexgc(5y)N/A
ROCE(3y)26.85%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.94
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | 6.91 | ||
| Debt/EBITDA | 0.48 | ||
| Cap/Depr | 58.09% | ||
| Cap/Sales | 3.63% | ||
| Interest Coverage | 14.7 | ||
| Cash Conversion | 19.24% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z | 1.51 |
F-Score5
WACC9.52%
ROIC/WACC2.29
Cap/Depr(3y)93.56%
Cap/Depr(5y)171.69%
Cap/Sales(3y)7.51%
Cap/Sales(5y)22.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.53%
EPS Next Y-75%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.78%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%39.21%
Revenue Next Year8.09%
Revenue Next 2Y16.75%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y510.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.13%
OCF growth 3YN/A
OCF growth 5YN/A